Objective: Psychedelics and psychedelic-assisted therapies (PATs) are on the cusp of becoming medicalized treatment modalities within the United States, both as potential U.S. Food and Drug Administration (FDA)-approved treatment and therapeutic options outside the medical model, through decriminalization efforts within individual states. Bringing with it a paradigm shift in the delivery of health care for both physical and mental health treatment. A workforce of highly trained facilitators will be needed to meet the anticipated demand for this type of treatment and nurses can play a key role in meeting this demand. This article serves to introduce psychedelic-assisted therapies to psychiatric-mental health nurses as we start to see this new field emerge.
Method: Review of published literature and other media.
Results: Results based on historical data, modern applications, and future considerations.
Conclusions: Nurses have been involved with psychedelic-assisted therapies in the past and are fully capable of providing a wide range of roles upon the anticipated approval as a treatment modality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10783903231222930 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychedelic-assisted therapy - supposedly paradigm-shifting research with poor attempts at hypotheses falsifying and questionable ethics.
EXCLI J
December 2024
Department of Biochemistry, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, Singapore.
Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.
Psychopharmacology (Berl)
January 2025
GGZ Research, Academic Center for Trauma and Personality, Amsterdam, Netherlands.
Rationale: Psychedelic-assisted therapy is increasingly applied within mental health treatment.
Objectives: This study focused on factors moderating changes in the acute and long-term effects of an individual psilocybin-assisted program on depression, anxiety, PTSD and personality structures by including demographic factors, subjective experience and degree of mystical type experiences during the dosing, as well as emotional breakthrough and personal growth after the program.
Methods: At baseline, 1 week and 3 months after the psilocybin program participants completed the Generalized Anxiety Disorder Assessment (GAD-7), Patient Health Questionnaire (PHQ-9), PTSD Checklist for DSM-5 (PCL-5) and NEO Five-Factor Inventory-3 (NEO-FFI-3).
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.
Am J Psychiatry
January 2025
Directorate of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, Md. (Wolfgang); Department of Psychiatry, Uniformed Services University, Bethesda, Md. (Wolfgang, Benedek); Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (Wolfgang, Wiechers); Department of Veterans Affairs, Office of Research and Development, Washington, D.C. (McClair, Smyth, Tenhula); Department of Veterans Affairs, Executive Division, National Center for PTSD, White River Junction, Vt. (Schnurr, Holtzheimer); Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, N.H. (Schnurr, Holtzheimer); Department of Psychiatry and Behavioral Sciences, University of California, San Francisco. (Woolley, Wiechers); San Francisco Veterans Affairs Medical Center, San Francisco. (Woolley); Department of Psychiatry, Oregon Health and Science University, Portland, Ore. (Stauffer); Department of Mental Health; VA Portland Health Care System, Portland, Ore. (Stauffer); Substance Abuse and Mental Health Services Administration, Rockville, Md. (Wolf); Department of Health and Human Services, Office of the Assistant Secretary for Health, Washington, D.C. (States); Department of Psychiatry, Harvard Medical School, Boston (Bradley); VA Boston Healthcare System, Boston (Bradley); Department of Veterans Affairs, Pharmacy Benefits Management Service, Washington, D.C. (Fuller); Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio (Fuller); Department of Veterans Affairs, Northeast Program Evaluation Center, Office of Mental Health, Washington, D.C. (Hermes); Veterans Health Administration Office of Mental Health, Washington, D.C. (Wiechers).
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research.
Am J Psychiatry
January 2025
Department of Psychiatry, NYU Grossman School of Medicine, New York (O'Donnell); NYU Langone Center for Psychedelic Medicine, New York (O'Donnell); University of Colorado Anschutz Medical Campus, Denver (Gringsby); Department of Psychiatry and Biobehavioral Sciences and Pediatrics, UCLA School of Medicine, Los Angeles (Grob).
Informed Consent in Psychedelic-Assisted Therapy.
Curr Top Behav Neurosci
December 2024
Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY, USA.
Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings. Interest has arisen in the use of classical psychedelics and entactogens, together termed "psychedelics," for therapeutic purposes in Western clinical settings.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!